Baseline patient characteristics
| . | PP (n = 50) . | RD (n = 33) . | ER (n = 48) . | LR (n = 42) . | P value* . |
|---|---|---|---|---|---|
| Age (y), median (interquartile range) | 64.8 (57.5-71.9) | 65.4 (61.7-71.0) | 65.5 (59.5-70.3) | 65.5 (60.0-69.6) | .97† |
| Sex, n (%) | |||||
| Male | 34 (68.0) | 21 (63.6) | 24 (50.0) | 18 (42.9) | .06 |
| Female | 16 (32.0) | 12 (36.4) | 24 (50.0) | 24 (57.1) | |
| Stage, n (%) | |||||
| Unknown | 1 (2.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | .53 |
| I/II | 7 (14.0) | 5 (15.2) | 12 (25.0) | 10 (23.8) | |
| III/IV | 42 (84.0) | 28 (84.8) | 36 (75.0) | 32 (76.2) | |
| Cell of origin by Hans algorithm, n (%) | |||||
| Unknown | 6 (12.0) | 2 (6.1) | 8 (16.7) | 12 (28.6) | .06 |
| GCB | 35 (70) | 23 (69.7) | 26 (54.2) | 18 (42.8) | |
| non-GCB | 9 (18.0) | 8 (24.2) | 14 (29.1) | 12 (28.6) | |
| DHL/THL, n (%) | |||||
| Unknown | 13 (26.0) | 6 (18.2) | 12 (25.0) | 12 (28.6) | .58 |
| Yes (DHL/THL) | 8 (16) | 10 (30.3) | 7 (14.6) | 6 (14.3) | |
| No | 29 (58.0) | 17 (51.5) | 29 (60.4) | 24 (57.1) | |
| R-IPI, n (%) | |||||
| Unknown | 6 (12.0) | 0 (0.0) | 2 (4.2) | 0 (0.0) | .008 |
| Very good (IPI = 0) | 0 (0.0) | 1 (3.0) | 4 (8.3) | 0 (0.0) | |
| Good (IPI = 1,2) | 13 (26.0) | 10 (30.3) | 15 (31.3) | 21 (50.0) | |
| Poor (IPI = 3,4,5) | 31 (62.0) | 22 (66.7) | 27 (56.3) | 21 (50.0) | |
| Prior lines of therapy, n (%) | |||||
| Unknown | 0 (0.0) | 0 (0.0) | 1 (2.1) | 0 (0.0) | .23 |
| 2 | 17 (34.0) | 12 (36.4) | 18 (37.5) | 11 (26.2) | |
| 3 | 14 (28.0) | 12 (36.4) | 9 (18.8) | 7 (16.7) | |
| 4+ | 19 (38.0) | 9 (27.2) | 20 (41.7) | 24 (57.1) | |
| Prior SCT, n (%) | |||||
| Unknown | 0 (0.0) | 0 (0.0) | 1 (2.1) | 1 (2.4) | .03 |
| Yes | 3 (6.0) | 7 (21.2) | 10 (20.8) | 14 (33.3) | |
| No | 47 (94.0) | 26 (78.8) | 37 (77.1) | 27 (64.3) | |
| CAR-T product, n (%) | |||||
| Axi-cel | 41 (82.0) | 31 (93.9) | 42 (87.5) | 33 (78.6) | .26 |
| Tisa-cel | 9 (18.0) | 2 (6.1) | 6 (12.5) | 9 (21.4) | |
| . | PP (n = 50) . | RD (n = 33) . | ER (n = 48) . | LR (n = 42) . | P value* . |
|---|---|---|---|---|---|
| Age (y), median (interquartile range) | 64.8 (57.5-71.9) | 65.4 (61.7-71.0) | 65.5 (59.5-70.3) | 65.5 (60.0-69.6) | .97† |
| Sex, n (%) | |||||
| Male | 34 (68.0) | 21 (63.6) | 24 (50.0) | 18 (42.9) | .06 |
| Female | 16 (32.0) | 12 (36.4) | 24 (50.0) | 24 (57.1) | |
| Stage, n (%) | |||||
| Unknown | 1 (2.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | .53 |
| I/II | 7 (14.0) | 5 (15.2) | 12 (25.0) | 10 (23.8) | |
| III/IV | 42 (84.0) | 28 (84.8) | 36 (75.0) | 32 (76.2) | |
| Cell of origin by Hans algorithm, n (%) | |||||
| Unknown | 6 (12.0) | 2 (6.1) | 8 (16.7) | 12 (28.6) | .06 |
| GCB | 35 (70) | 23 (69.7) | 26 (54.2) | 18 (42.8) | |
| non-GCB | 9 (18.0) | 8 (24.2) | 14 (29.1) | 12 (28.6) | |
| DHL/THL, n (%) | |||||
| Unknown | 13 (26.0) | 6 (18.2) | 12 (25.0) | 12 (28.6) | .58 |
| Yes (DHL/THL) | 8 (16) | 10 (30.3) | 7 (14.6) | 6 (14.3) | |
| No | 29 (58.0) | 17 (51.5) | 29 (60.4) | 24 (57.1) | |
| R-IPI, n (%) | |||||
| Unknown | 6 (12.0) | 0 (0.0) | 2 (4.2) | 0 (0.0) | .008 |
| Very good (IPI = 0) | 0 (0.0) | 1 (3.0) | 4 (8.3) | 0 (0.0) | |
| Good (IPI = 1,2) | 13 (26.0) | 10 (30.3) | 15 (31.3) | 21 (50.0) | |
| Poor (IPI = 3,4,5) | 31 (62.0) | 22 (66.7) | 27 (56.3) | 21 (50.0) | |
| Prior lines of therapy, n (%) | |||||
| Unknown | 0 (0.0) | 0 (0.0) | 1 (2.1) | 0 (0.0) | .23 |
| 2 | 17 (34.0) | 12 (36.4) | 18 (37.5) | 11 (26.2) | |
| 3 | 14 (28.0) | 12 (36.4) | 9 (18.8) | 7 (16.7) | |
| 4+ | 19 (38.0) | 9 (27.2) | 20 (41.7) | 24 (57.1) | |
| Prior SCT, n (%) | |||||
| Unknown | 0 (0.0) | 0 (0.0) | 1 (2.1) | 1 (2.4) | .03 |
| Yes | 3 (6.0) | 7 (21.2) | 10 (20.8) | 14 (33.3) | |
| No | 47 (94.0) | 26 (78.8) | 37 (77.1) | 27 (64.3) | |
| CAR-T product, n (%) | |||||
| Axi-cel | 41 (82.0) | 31 (93.9) | 42 (87.5) | 33 (78.6) | .26 |
| Tisa-cel | 9 (18.0) | 2 (6.1) | 6 (12.5) | 9 (21.4) | |